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The absence of orexin results in narcolepsy-cata-
plexy. While the function of the central orexinergic
system in sleep regulation has been well studied,
the role of orexin in motor control is largely unknown.
Here, we show that orexin-A acts via OX1 and OX2
receptors to directly depolarize neurons in the rat
lateral vestibular nucleus (LVN), a subcortical motor
center, and enhance their sensitivity. A dual ionic
mechanism involving both Na+-Ca2+ exchangers
and inward rectifier K+ channels underlies these
effects. Furthermore, orexin-A regulates central
vestibular-mediated posture, motor balance and
negative geotaxis. Orexin is critical when an animal
is facing a major motor challenge as opposed to
during rest and general movements. Therefore,
orexin participates not only in sleep and emotion
(nonsomatic) but also in motor (somatic) regulation,
suggesting that the central orexinergic system plays
an important role in somatic-nonsomatic integration.
These findings may account for why the absence of
orexin results in narcolepsy-cataplexy.
INTRODUCTION
The last decade has witnessed significant advances in our
understanding of the physiological roles of orexin (also known
as hypocretin), a neuropeptide first identified in 1998 (de Lecea
et al., 1998; Sakurai et al., 1998). As a neurotransmitter system
originating uniquely from the lateral hypothalamus/perifornical
area but projecting extensively to almost the whole brain
(Broberger et al., 1998; Cutler et al., 1999; Peyron et al., 1998),
the central orexinergic system has been implicated in many
basic nonsomatic functions, including the sleep/wake states,
feeding, and reward processes (Kukkonen et al., 2002; Matsuki
and Sakurai, 2008; Sakurai, 2007). However, whether the central
orexinergic system has a role in somatic motor control remains
enigmatic.
Orexin knockout mice exhibit normal movement initiation and
speed (Espan˜a et al., 2007) with only a slight decrease in motor
activity compared with wild-type animals (Hara et al., 2001;Mieda et al., 2004; Mochizuki et al., 2004). However, intriguingly,
orexin deficiency in humans, dogs, and rodents results in cata-
plexy, a motor deficit characterized by sudden loss of muscle
tone (Chemelli et al., 1999; Sakurai, 2007), highlighting the possi-
bility of a modulatory role for orexin in motor control. But, since
cataplexy is closely related to narcolepsy and often triggered
by strong emotions, the effect of orexin on the motor system
may be secondary to its actions on the neural circuits controlling
sleep or emotions (Espan˜a et al., 2007; Hagan et al., 1999;
Kiyashchenko et al., 2002; Matsuki and Sakurai, 2008).
However, several lines of evidence indicate that the orexiner-
gic systemmay directly participate in central motor control. First,
numerous neuroanatomical and immunohistochemical studies
reveal that essential subcortical motor structures, such as basal
ganglia, cerebellum, and vestibular nuclei, receive direct inner-
vation from the hypothalamic orexinergic neurons (Cutler et al.,
1999; Peyron et al., 1998). Second, during movements, orexiner-
gic neurons are particularly active (Estabrooke et al., 2001; Lee
et al., 2005; Mileykovskiy et al., 2005; Torterolo et al., 2003)
and orexin release increases (Kiyashchenko et al., 2002; Martins
et al., 2004; Wu et al., 2002). Finally, injection of orexin into the
midbrain locomotor region of decerebrate cats triggers locomo-
tion and facilitates muscle tone (Takakusaki et al., 2005). Thus,
the role of central orexinergic system in motor control needs to
be clarified.
In the present study, to reveal the exact relationship between
the central orexinergic system and motor control, the effects of
orexin on the motor system and the underlying mechanisms
were investigated at molecular, cellular, and behavioral levels.
Considering that cataplexy induced by orexin deficiency is char-
acterized by sudden loss of muscle tone and the central vestib-
ular system plays a critical role in control of muscle tone and
postural control (Angelaki and Cullen, 2008; Barmack, 2003),
we focused on the effects of orexin on the vestibular nuclear
complex in the brainstem. Moreover, compared to other senso-
rimotor circuits, the central vestibular circuitry exhibits a linear
input-output transformation which is closely linked to vestibular
reflexes (Bagnall et al., 2008). This distinctive feature enables any
modulation on the vestibular nuclei, including orexinergic, to be
linearly transduced into the final output of the vestibular circuitry
and reflected in motor behavior. Therefore, this study, we
concentrated on the lateral vestibular nucleus (LVN, or Deiters’
nucleus) in the vestibular nuclear complex, a nucleus that directly
contributes to adjustment of muscle tone for both postural main-
tenance and the alternative change from the extensor to theNeuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc. 793
Figure 1. OX1 and OX2 Receptors Are Expressed in LVN and Local-
ized in Giant Neurons
(A) Sagittal view of the rat brain (Paxinos andWatson, 2007), localizing the LVN
between 10.30 and 11.60 mm from the bregma. LVN tissue punches for
analysis of expression of ox-r1 and ox-r2 were collected from brain slices
obtained using these coordinates.
(B) Diagram of coronal brainstem sections from rostral to caudal levels shows
the area of the LVN investigated in this RT-PCR as well as the following
electrophysiological studies.
(C) Amplification curves for ox-r1 (red), ox-r2 (blue), and gapdh (black) were
obtained to identify the cycle thresholds (Ct) at which reporter fluorescence
intensity significantly exceeded background fluorescence signals.
(D) A melting temperature curve analysis was performed to determine that
the reactions yielded only one product per gene. Each peak corresponds to
the melting temperature of ox-r1 (red), ox-r2 (blue), or gapdh (black).
(E) Bar graphs showing relative expression of ox-r1 and ox-r2 in LVN.
(F1–F3) Antibody staining for OX1 receptors in the rat LVN.
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Wilson and Peterson, 1978). Carrying out quantitative real-time
reverse transcription-polymerase chain reaction (RT-PCR) and
immunofluorescence techniques, we first investigated expres-
sion and distribution of orexin receptors in the LVN in rats.
Next, we examined in brain slices the electrophysiological
effects of orexin on the LVN neurons using whole-cell patch-
clamp recordings. Finally, we determined whether orexin
regulates vestibular-mediated motor behaviors. The results
demonstrate that orexin activates LVN neurons and promotes
vestibular-mediated motor behaviors, implicating orexin and
the central orexinergic system in the direct control of somatic
motor behavior.
RESULTS
Both OX1 and OX2 Receptors Are Expressed
in the LVN and Localized in Giant Neurons
We assessed the expression of OX1 and OX2 receptor mRNAs in
rat LVN by quantitative real-time RT-PCR. The rat LVN tissues,
localized between10.50 and11.30mm from bregma (Figures
1A and 1B), were extracted according to the rat brain atlas of
Paxinos and Watson (2007). Amplification and melting tempera-
ture curves of ox-r1 and ox-r2 (genes of OX1 and OX2 receptors)
and gapdh (the control housekeeping gene) show the cycle
thresholds (Ct) for all genes (Figure 1C) and demonstrate that
only one product per gene was generated (Figure 1D). As shown
in Figure 1E, both OX1 and OX2 receptor mRNAs were detected
in the rat LVN.
To map the distribution of orexin receptors, we performed
immunostaining of the rat brain slices containing the LVN with
an antibody against OX1 and OX2 receptors, respectively. We
found that both OX1 and OX2 receptors were localized in the
LVN (Figures 1F1, 1F2, 1G1, and 1G2) and present in all the large
neurons (diameter >35 mm) (Figures 1F3 and 1G3). These large
neurons are giant Deiters’ neurons (Shamboul, 1979; Sua´rez
et al., 1993), whose axons form an important part of the posterior
longitudinal bundle that controls the vestibulospinal reflexes.
Orexin-A Excites LVN Neurons by Activation of Both OX1
and OX2 Receptors
Given the finding of the expression and localization of the orexin
receptors in the LVN and considering previous reports of moder-
ately dense orexinergic innervation of the vestibular nuclei in rats
(Cutler et al., 1999; Peyron et al., 1998), we carried out voltage-
clamp recordings in the giant LVN neurons (diameter >35 mm) to
examine the effect of orexin on whole-cell currents of LVN
neurons and the underlying mechanisms by using brain slice
preparations (see also Figure 1B). In total, we recorded 69 LVN
neurons with the membrane resistance higher than 150 MU. As(G1–G3) Antibody staining for OX2 receptors in the rat LVN. Note that both OX1
and OX2 receptor immunostainings particularly enriched in the large-size LVN
neurons (diameter > 35 mm).
(H1–H3) Negative staining control by omitting the primary antiserum.
Scale bars: (F1), (G1), and (H1), 750 mm; (F2), (G2), and (H2), 195 mm; (F3), (G3),
and (H3), 23 mm. 4V, 4th ventricle; g7, genu of the facial nerve; icp, inferior cere-
bellar peduncle; LVN, lateral vestibular nucleus; sp5, spinal trigeminal tract.
Figure 2. Inward Whole-Cell Currents of LVN Neurons Induced by
Orexin-A through Activation of Both OX1 and OX2 Receptors
(A1) Orexin-A dose dependently elicited an inward current in a LVN neuron.
(A2) Concentration-response curve for orexin-A on 14 recorded LVN neurons
show the mean EC50 of 59.0 ± 17.9 nM.
(B) Similar to orexin-A, orexin-B also elicited an inward current on a LVN
neuron.
(C) Selective OX2 receptor agonist [Ala
11, D-Leu15]-orexin-B concentration-
dependently mimicked the orexin-A-induced inward current, and selective
OX1 receptor antagonist SB334867 partly blocked the orexin-A-induced
inward current on a LVN neuron, indicating orexin excites the LVN neurons
by activation of both OX1 and OX2 receptors.
In this and the following figures, the short horizontal bars above the data
indicate the 1 min period of application of orexin-A or orexin receptor agonist,
and the long horizontal bars indicate the exposure of the slice to TTX, orexin
receptor antagonist, or ion exchanger/channel inhibitors.
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membrane capacitance >150 pF, we conclude that the neurons
studied were giant Deiters’ neurons (Uno et al., 2003; Zhang
et al., 2008).
Orexins have two splice variants, orexin-A and orexin-B, that
are derived from a common pre-pro-orexin gene (Kukkonen
et al., 2002; Sakurai, 2007). Both orexin-A and orexin-B act on
two G protein-coupled receptors, OX1 and OX2 receptors
(Kukkonen et al., 2002; Sakurai, 2007). We found that brief appli-
cation (1 min) of orexin-A (10–300 nM) elicited a significant
inward whole-cell current on a majority of the recorded LVN
neurons (63/69, 91.3%). For the remaining six neurons, orexin-
A induced an outward current (3/69, 4.3%) or had no effect
(3/69, 4.3%). The orexin-A-induced excitation on LVN neurons
was concentration-dependent (Figures 2A1 and 2A2). Applica-
tion of 30, 50, 100 nM orexin-A elicited an inward current of
–38.4 ± 5.9 pA (n = 8), –53.4 ± 9.6 pA (n = 7), –73.8 ± 13.0 pA
(n = 7), respectively. Fitting the concentration-response curve
from 14 LVN neurons yielded that the mean concentration of
orexin-A for half-maximal activation (EC50) was 59.0 ± 17.9 nM.
Additionally, the effect of orexin-B on the LVN neurons (n = 6)
was similar to that of orexin-A (Figure 2B).
We used a selective receptor agonist and antagonist to assess
the underlying receptor mechanisms, although the choice of
orexinergic agents is limited as only [Ala11, D-Leu15]-orexin-B
(selective OX2 receptor agonist) and SB334867 (selective OX1
receptor antagonist) are commercially available. As shown in
Figure 2C, [Ala11, D-Leu15]-orexin-B mimicked the orexin-A-
induced excitatory effect on LVN neurons. On 6 LVN neurons,
100 and 300 nM [Ala11, D-Leu15]-orexin-B elicited a concentra-
tion-dependent inward current of –26.5 ± 2.2 pA and –71.6 ±
6.6 pA, respectively, suggesting that OX2 receptors are involved
in the action of orexin on the LVN neurons. In addition, on the
same six LVN neurons, the orexin-A-elicited inward currents
were partly blocked by SB334867. After application of 10 mM
SB334867, 30 nM orexin-A-elicited currents decreased from
–43.4 ± 6.2 pA to –22.2 ± 2.9 pA (p < 0.01). Together, these
results provide direct electrophysiological evidence that orexin
excites the LVN neurons by activation of both OX1 and OX2
receptors, consistent with our molecular and immunostaining
results.
Orexin-A Excites the LVN Neurons via a Dual
Ionic Mechanism
To clarify the ionic basis underlying the orexin-induced excita-
tion, first we determined whether the action of orexin-A on the
LVN neurons was a direct postsynaptic effect. The fact that
application of orexin-A onto LVN neurons evokes a stable inward
current instead of EPSC/IPSCs suggests a direct postsynaptic
excitatory effect. We also used 0.3 mM TTX for confirmation.
As shown in Figures 3A and 3B1, TTX did not block the
100 nM orexin-A-elicited inward currents (i.e., –71.8 ± 10.7 pA
and –69.4 ± 9.4 pA before and after applying TTX, p = 0.212;
n = 5), strongly suggesting that the excitation of orexin on the
LVN neurons is a direct postsynaptic action. Furthermore,
GABAA receptor (100 mM picrotoxin) and ionotropic glutamate
receptor (1 mM kynurenate) antagonists still did not influence
the orexin-elicited inward current (i.e., –72.3 ± 22.0 pANeuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc. 795
Figure 3. More Than One Ionic Basis Is Involved in Orexin-A-Elicited
Inward Currents on LVN Neurons
(A) TTX did not block the orexin-A-induced inward current and affect the
accompanied membrane conductance decrease on a LVN neuron, indicating
orexin-A caused a decrease of activity of ion channels on the postsynaptic
membrane.
(B1 and B2) Group data of 5 tested LVN neurons.
(C1–C4) Four types of orexin-A-induced changes of I-V curves on LVN
neurons. The I-V curves were acquired by recording the response of the cells
to a slow ramp command (dV/dt = –10 mV/s) in the absence and presence of
orexin. (C1) This I-V relationship change was observed in 55.6% (10/18) of
these neurons tested, the orexin-A-induced inward current was smaller at
the more hyperpolarized potential of –120 mV than at –65 mV. (C2) In 22.2%
(4/18) of neurons, the orexin-A-induced inward current had a larger amplitude
at –120 mV as compared with –65 mV. (C3) In 16.7% (3/18) of neurons,
the orexin-A-induced inward current reversed near the calculated Ek of
–105 mV; C4, In the remaining one neuron, the orexin-A-elicited inward current
was similar in amplitude at –65 and –120 mV, although its amplitude first
decreased then increased along with the hyperpolarization. The diversity of
the orexin-A-induced changes in I-V relationships suggests that more than
one ionic basis is involved in orexin-A-elicited inward currents on LVN neurons.
Neuron
Role for Orexin in Central Motor Control
796 Neuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc.and –73.5 ± 25.3 pA before and after application, p = 0.811;
n = 4; see Figure S1 available online), confirming the direct post-
synaptic mechanism. Moreover, accompanying the orexin-A-
induced inward currents, the input conductance of the cells
slightly decreased (76.4% ± 6.3% of the control; Figures 3A
and 3B2), and the change of conductance was not blocked by
TTX (77.4% ± 5.9% of the control, p = 0.234; Figures 3A and
3B2), suggesting that orexin-A caused a closure of ion channels
on the postsynaptic membrane.
Next, we determined the I-V curves in response to orexin-A to
investigate the underlying ionic mechanism. We employed slow
ramp command tests (dV/dt = –10 mV/s, ranged from –65 mV to
–120 mV) to evaluate the I-V curves for a large voltage range in
the absence and presence of orexin-A. We observed four types
of orexin-A-induced changes on the I-V curves from 18 LVN
neurons. Among 55.6% (10/18) of these neurons, the orexin-A-
elicited inward current was smaller at the more hyperpolarized
potential of –120 mV as compared with –65 mV (Figure 3C1),
and in 22.2% (4/18) of neurons, the orexin-A-induced inward
current had a larger amplitude at –120 mV as compared with
–65 mV (Figure 3C2). In 16.7% (3/18) of the neurons tested,
orexin-A elicited an inward current that reversed near the calcu-
lated Ek of –105 mV (Figure 3C3), suggesting the involvement of
K+ channels. In the remaining 1 neuron, the orexin-A-elicited
inward current was similar in amplitude at –65 and –120 mV,
although its amplitude first decreased then increased along
with the hyperpolarization (Figure 3C4). The diversity of the
changes in the I-V curves implies that more than one ionic mech-
anism is involved in the orexin-induced excitation on the LVN
neurons, in which K+ may be an important component.
Blockage of K+ channels, activation of nonselective cation
channels and/or electrogenic Na+-Ca2+ exchangers have been
reported to mediate the orexin-A-elicited inward current
(Eriksson et al., 2001; Liu et al., 2002; Wu et al., 2004). Notably,
decrease of input conductance (see Figures 3A and 3B2) and the
reversal potential near the calculated Ek (see Figure 3C3)
together indicate that orexin-A suppressed K+ channels to excite
LVN neurons. Furthermore, we assessed other ionic mechanism
(s) underlying the excitatory effects of orexin on LVN neurons.
We applied a selective blocker of Na+-Ca2+ exchangers (50 mM
KB-R7943) on 6 LVN neurons and observed a partial inhibition
of the orexin-A-elicited inward current (49.0% ± 5.4% of the
control) (Figures 4A and 4D), suggesting an activation of
electrogenic Na+-Ca2+ exchangers. Then, under a condition of
blockage of Na+-Ca2+ exchangers by continuously perfusing
the slice with KB-R7943, we used slow ramp command tests
to obtain the I-V curves in the absence and presence of orexin-
A (the left panel of Figure 4B1). Subtracting the control from
the current recorded during orexin-A application yielded a
difference current representing the orexin-A-induced current
excluding the component of Na+-Ca2+ exchangers (the right
panel of Figure 4B1). The difference current obtained from the
6 LVN neurons (Figure 4B2) exhibited two significant features:
the difference current had a reversal potential of –100 mV thatError bars represent SEM; n.s. indicates nonsignificant and *p < 0.05. See also
Figure S1.
Figure 4. Dual Ionic Mechanisms Including Activation of the Na+-
Ca2+ Exchanger and Block of an Inward Rectifier K+ Current Mediate
the Effects of Orexin-A on LVN Neurons
(A) KB-R7943, a selective blocker of Na+-Ca2+ exchangers, partly blocked the
orexin-A-induced inward current on a LVN neuron, suggesting orexin activated
electrogenic Na+-Ca2+ exchangers.
(B1) The I-V relationship of orexin-A-induced current in the ACSF containing
KB-R7943. The difference current (orexin-A-induced current, right panel)
was obtained by subtracting the control current from the current recorded
during orexin-A application (left panel). (B2) Group data of the orexin-A-
induced currents on 6 tested LVN neurons. Note that in the presence of KB-
R7943, the orexin-A-induced current showed an outward rectification and
reversed at the potential of 100 mV, which was near the calculated Ek, indi-
cating orexin blocked the inward rectifier K+ channels.
(C) KB-R7943 and Ba2+, a blocker of K+ channels, totally blocked orexin-A-
induced inward current on a LVN neuron, suggesting the orexin-A excited
the LVN neurons via a dual ionic mechanism including both activation of
Na+-Ca2+ exchangers and closure of inward rectifier K+ channels.
(D) The effects of KB-R7943 and Ba2+ on orexin-A-induced inward current in
tested LVN neurons were summarized.
Error bars represent SEM; **p < 0.01. See also Figure S2.
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fying. Considering orexin-A decreased input conductance, the
result indicates that the K+ channels blocked by orexin-A are
the inward rectifier K+ channels. To confirm these results, we
applied Ba2+ (1 mM), a blocker of K+ channels, combined with
50 mM KB-R7943, on 5 LVN neurons. The orexin-A-elicited
inward current was nearly totally blocked (10.5% ± 2.6% of
the control) (Figures 4C and 4D), suggesting that orexin-A
excites the LVN neurons via a dual ionic mechanism, including
both activation of Na+-Ca2+ exchangers and closure of inward
rectifier K+ channels. Other two specific blockers for Na+-Ca2+
exchangers (10 mM SN-6) and inward rectifier K+ channels
(100 nM tertiapin-Q) further confirmed the dual ionic mechanism
(Figure S2).
Orexin-A Directly Increases Activities and Sensitivities
of LVN Neurons
Given that orexin-A induces an inward current on the LVN
neurons, we carried out current clamp experiments to address
whether orexin-A directly activates LVN neurons. The LVN
contains two classes of neurons, one that has spontaneous
discharge and the other (30%–50% of neurons) that has no
spontaneous discharge (Uno et al., 2003; Zhang et al.,
2008). As expected, orexin-A (100 nM) elicited a significant
increase in the discharge rates of 4 LVN spontaneous firing
neurons (Figure 5A), and a sufficiently strong depolarization to
activate firing in two silent neurons (Figure 5B). Plotting the
interspike intervals (ISIs) and peristimulus time histograms
(PSTHs) of the LVN neurons with spontaneous firing (Figures
5C and 5D) shows that, accompanied by a remarkable increase
in the peak firing rates (146.9% ± 15.6% of the baseline of
6.8 ± 1.8 spikes/s), the spiking intervals were also significantly
shortened by orexin-A. Therefore, orexin directly increases
the firing of both spontaneous discharges and silent LVN
neurons.
Intriguingly, orexin-A also increased the sensitivity of the LVN
neurons to a depolarizing ramp-like current stimulation (Fig-
ure 5E1), consisting of a 600 ms ramp (150 pA to 150 pA,
slope of 0.5 nA/s) followed by a long plateau of current
(150 pA, 4400 ms) (Ris et al., 2001; Uno et al., 2003). On
5 LVN neurons, orexin-A (100 nM) significantly shortened the
first-spike latency from 449.3 ± 47.2 ms to 281.3 ± 35.4 ms
(p < 0.05; Figure 5E2). Furthermore, orexin-A increased the
rate of increase in the instantaneous firing rate (Figure 5E3)
of the LVN neurons from 29.2 ± 9.1 spikes/s/nA to 34.4 ±
9.4 spikes/s/nA (p < 0.01; Figure 5E4), consistent with an
increase in the sensitivity of the cell to the current stimulation.
However, orexin-A did not change (control, 1.70 ± 0.40 spikes/s;
orexin-A, 1.53 ± 0.45 spikes/s, p = 0.132; Figure 5E5) the differ-
ence between the firing rate reached at the end of the ramp and
the stable discharge rate reached at the end of the plateau (over-
shoot in spikes/s; Figure 5E3), i.e., orexin did not change the
accommodation, which gives an indication of the unchanged
dynamic properties of neurons by orexin. The increase in both
the firing rate and sensitivity of LVN neurons suggests that the
orexinergic afferent system in the LVN may have a potential
physiological function on the vestibular-mediated motor
behaviors.Neuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc. 797
Figure 5. Orexin-A Directly Increases Activ-
ities and Sensitivities of LVN Neurons
(A) Orexin-A excited a LVN spontaneous firing
neuron.
(B) Orexin-A excited another LVN silent neuron.
The inset showed a strong depolarization induced
by orexin-A.
(C) ISI and PSTH showed that orexin-A shortened
the inter-spike intervals and increased the firing
rate of the LVN neuron presented in (A).
(D) Group data of four tested LVN neurons.
(E1–E5) Orexin-A increased sensitivities of the
LVN neurons to a depolarizing ramp-like current
stimulation. (E1) A ramp-like current was given
from a hyperpolarized level of 150 pA for
600 ms to reach +150 pA, with the final steady-
state value of +150 pA lasting 4400 ms. (E2)
Orexin-A significantly shortened the first-spike
latency of a LVN neuron to the ramp-like current.
(E3) Instantaneous firing rates of the same LVN
neuron to the ramp-like current in the absence
and presence of orexin-A showed that orexin
remarkably raised the rate of increase of the
instantaneous firing rate (spikes/s/nA) but did not
influence the overshooting response, suggesting
an increase of sensitivity and unchanged nonlinear
dynamic property of LVN neurons by orexin-A.
(E4 and E5) Group data of 5 tested LVN neurons.
Error bars represent SEM; n.s. indicates nonsignif-
icant and **p < 0.01.
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Vestibular-Related Motor Behaviors
We microinjected orexin-A (10 mM, 1 ml) into the LVN and used
extracellular recording to observe its actions in vivo in
urethane-anesthetized rats. To estimate the effective extent of
diffusion of the injected compounds in the LVN, units from
0.5–2.0 mm away from the injection sites were recorded (Song
et al., 2006). Orexin-A significantly excited 6 of 8 recorded LVN
neurons (75%) that were close (0.5–1.3 mm) to the injection
site while vehicle (1 ml) had no effect (n = 6) (Figure 6A2), suggest-
ing that orexin endogenously released from afferent fibers may
directly regulate the firing of LVN neurons. The mean latency of
the orexin-induced excitatory effects on LVN neurons in vivo
was 95 ± 6 s (ranged from 78 to 115 s), whereas the mean dura-
tion was 681 ± 303 s (ranged from 150 to 1310 s). There was
a negative correlation between the duration and latency of the
orexin-induced excitatory responses on LVN neurons (linear
regression, r = 0.980), implicating a spread of microinjected
orexin in the LVN. Microinjection of orexin-A (n = 8) and vehicle798 Neuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc.(n = 8) did not induce neurons near the
inner edge of the LVN (1.5–2.0 mm away
from the injection site) any changes in
discharge frequency (Figures 6A1 and
6A3), indicating the present microinjec-
tions, which were also applied in the
following behavioral studies, only acti-
vated neurons strictly located in the
LVN. Representative coronal histological
sections from the rat brain showing twoinjection sites in the superficial LVN, the tracts of the guide tubes
above the bilateral nuclei, and the reconstructed microinjection
sites within the LVN (n = 174 in each side) are presented in
Figures 6B and 6C, respectively.
Because of the key position of the LVN in the vestibulospinal
reflexes and posture control, we asked whether the excitatory
effect of orexin on LVN neurons influences vestibular-mediated
behaviors. Unilateral microinjection of orexin-A (10 mM, 1 ml)
into the rat LVN induced an obvious postural syndrome showing
a tilt of head and body to the contralateral side with extension of
the ipsilateral limbs, consistent with increased firing of the
ipsilateral LVN. Furthermore, we counted the rotation numbers
for 5 min by hanging the rat by its tail with its forepaws on the
ground, and found that the rotations in the contralateral direction
of the rats unilaterally microinjected with orexin-A (32.42 ± 2.63)
were significantly increased (one-way ANOVA, F(2,33) = 112.47,
p < 0.01) compared to those of the vehicle-treated group
(4.33 ± 0.67) or the sham operated animals (4.83 ± 0.61) (Fig-
ure 6D). The results strongly indicate that through directly
Figure 6. Orexin-A Excites the LVN Neurons In Vivo and Improves
Vestibular-Related Motor Behaviors
(A1–A3) Dot raster plots showed unitary activity of LVN neurons continuously
recorded in vivo before and after microinjection of vehicle and orexin-A.
Neurons near the inner edge of the LVN did not exhibit any changes in firing
rate following vehicle and orexin-A microinjections (A1 and A3), whereas
a neuron recorded close to the injecting site within the LVN exhibited a signif-
icant excitatory response to injection of orexin-A rather than vehicle (A2). Each
arrowhead indicates the injection which lasts for 2 min.
(B) A coronal section (80 mm in thickness) of rat brainstem showing the sites of
microinjection within the superficial LVN (indicated by the arrowhead). The
bloodstain presents the traces of guide tubes that were positioned 2 mm
above the LVN.
(C) Histological reconstruction showing the microinjection sites (indicated by
the arrowhead) across 84 animals.
(D) Rotations in the contralateral direction of rats treated by unilateral micro-
injection of orexin-A and vehicle into the LVN and of sham operated group.
(E and F) The duration of passage through the horizontal balance beam and the
time necessary to turn to 180 upward from an initial position with animals’
heads facing downward on an incline of sham operated rats and rats treated
by bilateral microinjection of orexin-A and vehicle into the LVN.
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LVN and consequently change body posture.
Next, since the LVN contributes not only static but also to
dynamic postural changes during vestibulospinal reflexes
(Molina-Negro et al., 1980; Wilson and Peterson, 1978), we
microinjected orexin-A (10 mM, 1 ml for each side) into the bilat-
eral LVNs in rats to observe whether orexin influences motor
behaviors in the horizontal balance beam and negative geotaxis
tests. Both tests assess motor balance and coordination as well
as vestibular function (Altman and Sudarshan, 1975; Hermans
et al., 1992). Orexin, rather than vehicle, immediately and signif-
icantly shortened the time that rats spent traversing the hori-
zontal balance beam and the performance recovered in hours
(repeated-measures two-way ANOVA: treatment, F(2,45) = 1.390,
p = 0.260; time, F(3,135) = 9.139, p < 0.001; interaction, F(6,135) =
6.457, p < 0.001; Newman-Keuls post hoc testing revealed
significant differences between the orexin-A injection group
and sham or vehicle group at 0 hr after injection, p < 0.01; Fig-
ure 6E). Moreover, in the negative geotaxis tests on a 40 incline,
orexin reduced the time necessary to turn to 180 upward from
an initial position with animals’ heads facing downward and
the performance also recovered in hours (repeated-measures
two-way ANOVA, treatment, F(2,51) = 1.145, p = 0.326; time,
F(3,153) = 4.877, p < 0.004; interaction, F(6,153) = 7.413, p < 0.001;
Newman-Keuls post hoc testing indicated significant differences
between the orexin-A injection group and sham or vehicle group
at 0 hr after injection, p < 0.05 and 0.01, respectively; Figure 6F).
The improvement in vestibular-mediated balance and coordina-
tion suggests that orexin modulates neuronal activity and sensi-
tivity of the LVN and contributes directly to vestibular-mediated
motor and postural control.
Microinjection of SB334867 into the LVN Strongly
Attenuates Rat Motor Performance during a Motor
Challenge Rather Than General Movements
To further clarify how endogenous orexin modulates vestibular-
mediated motor and postural control, we microinjected
SB334867 (5 mM, 1 ml), a selective OX1 receptor antagonist,
into the rat LVN bilaterally. Interestingly, SB334867 did not affect
rat motor performance in either the horizontal balance beam
(repeated-measures two-way ANOVA, treatment, F(2,27) =
0.066, p = 0.936; time, F(3,81) = 0.139, p = 0.937; interaction,
F(6,81) = 0.563, p = 0.758) or negative geotaxis (repeated-mea-
sures two-way ANOVA, treatment, F(2,27) = 0.035, p = 0.966;
time, F(3,81) = 1.022, p = 0.387; interaction, F(6,81) = 0.769,
p = 0.596) (Figures 7A and 7B). Nor did SB334867 elicit any
inhibition of neuronal firing in the LVN (n = 7; Figures S3A and
S3B) in the urethane-anesthetized rats, indicating that endoge-
nous orexin may have no effect on the LVN under the conditions
of resting or general movements.
Furthermore, considering that cataplexy induced by orexin
deficiency is often triggered by a strong stimulus, we speculated
that endogenous orexin may be critical for motor control when
animals face a motor challenge rather than under rest conditionsError bars represent SEM; n.s. indicates nonsignificant; *p < 0.05 and
**p < 0.01.
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Figure 7. SB334867 Strongly Attenuates Rat Motor Performance
during a Major Motor Challenge Rather Than General Movements
(A and B) The duration of passage through the balance beam and the time
necessary to turn to 180 upward from an initial position with animals’ heads
facing downward on an incline of sham operated rats and rats treated by bilat-
eral microinjection of SB334867 and vehicle into the LVN.
(C) Bilateral microinjection of SB334867 into the LVN immediately and signifi-
cantly increased the time that rats spent traversing the inclined balance beam
at 40. The inhibitory effect of SB334867 recovered in hours.
(D) In test using an acceleration of 0.2 rpm/s, bilateral microinjection of
SB334867 into the LVN immediately and significantly shortened the time
that rats stayed on an accelerating rota-rod. The inhibitory effect of
SB334867 also recovered in hours.
(E) The decrement of motor performance in accelerating rota-rod tests
increased with the increase of the acceleration.
(F) Both the spontaneous locomotor activities and the exploratory activities
were not affected by SB334867 in an open field.
Error bars represent SEM; n.s. indicates nonsignificant; *p < 0.05 and
**p < 0.01. See also Figure S3.
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used a modified inclined balance beam test at 40 as a greater
motor challenge than horizontal balance beam and negative
geotaxis. Consistent with the hypothesis, bilateral microinjection
of SB334867 into the LVN immediately and significantly
increased the time that rats spent traversing the inclined balance
beam (repeated-measures two-way ANOVA, treatment, F(2,27) =
0.322, p = 0.728; time, F(3,81) = 44.418, p < 0.001; interaction,
F(6,81) = 38.637, p < 0.001; Newman-Keuls post hoc testing
indicated significant differences between SB334867 injection
group and sham or vehicle group at 0 hr after injection,
p < 0.05; Figure 7C). The inhibitory effect of SB334867 on the
motor behavior recovered in hours (Figure 7C).
To investigate another significant motor challenge, we em-
ployed an accelerating rota-rod test, used three different
accelerations (0.12, 0.2, and 0.6 rpm/s). In test using an acceler-
ation of 0.2 rpm/s, bilateral microinjection of SB334867 into
the LVN immediately and significantly shortened the time that
rats stayed on the accelerating rota-rod (repeated-measures
two-way ANOVA, treatment, F(2,27) = 1.243, p = 0.304; time,
F(3,81) = 11.562, p < 0.001; interaction, F(6,81) = 13.494, p < 0.001;
Newman-Keuls post hoc testing indicated significant differences
between SB334867 injection group and sham or vehicle group
at 0 hr after injection, p < 0.01; Figure 7D). The inhibitory effect
of SB334867 on the motor behavior also recovered in hours
(Figure 7D). In test using an acceleration of 0.12 or 0.6 rpm/s,
there were the similar inhibitory effects of SB334867 (Figures
S3C and S3D). Moreover, intriguingly, the decrement of motor
performance in accelerating rota-rod tests increased with the
increase of the acceleration (Figure 7E), suggesting that
the stronger the motor challenge faced by animals, the greater
the degree of involvement of the central orexinergic system in
motor control.
In addition, both spontaneous locomotor (one-way ANOVA,
F(2,27) = 0.659, p = 0.525) and exploratory activity (one-way
ANOVA, F(2,27) = 0.257, p = 0.775) in an open-field were not
affected bymicroinjecting SB334867 into the bilateral LVNs (Fig-
ure 7F). The results confirm that endogenous orexin is involved in
the execution of challenging movements but not under resting
conditions or for the execution of general movements. They
also show that orexin acts through the LVN rather than as
a secondary effect on arousal or emotion.
DISCUSSION
The occurrence of narcolepsy-cataplexy in the orexin knockout
animals provides themost important clue for elucidating the rela-
tionship between the central orexinergic system and motor
control (Chemelli et al., 1999; Sakurai, 2007). However, the
effects of orexin on sleep and/or emotion systems cannot be
excluded. In the present study, we describe a role for the orexi-
nergic system in central vestibular-mediatedmotor control. First,
we found that both OX1 and OX2 receptors are expressed and
localized in the LVN. Together with previous observations of
orexinergic fibers in the vestibular nuclei (Cutler et al., 1999;
Peyron et al., 1998), these results confirm that there is an orexi-
nergic innervation of the LVN. Second, in vitro and in vivo electro-
physiological experiments demonstrate that orexin excites the
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Through a dual ionic mechanism, orexin increases the activity
and the sensitivity of LVN neurons. Finally, we demonstrated
significant orexin-induced postural changes and improvement
inmotor performances, with endogenous orexin playing a critical
role in motor control when animals face amajor motor challenge.
These results provide strong evidence that the central orexiner-
gic system is directly and actively involved in motor control.
Mechanism and Function of Orexin on LVN
Except for the suppression of glucose-responsive neurons in the
ventromedial hypothalamic nucleus (Shiraishi et al., 2000), orexin
excites almost all target neurons in the central nervous system
(Kukkonen et al., 2002; Sakurai, 2007), including Deiters’
neurons in the LVN. The ionic mechanisms for the action of
orexin on these neurons include presynaptic effects (increased
transmitter release via unknown mechanisms) and/or postsyn-
aptic depolarization. The stable currents and lack of effect of
TTX, picrotoxin, and kynurenate we observed in this study
strongly suggest that the inward currents elicited by orexin in
LVN neurons reflect direct postsynaptic excitation, although
the effect of orexin on vestibular nerve inputs to LVN neurons
in vivo is still unclear. It is well known that the postsynaptic signal
transduction pathways coupled with OX1 or OX2 receptors are
complex (Kukkonen et al., 2002; Matsuki and Sakurai, 2008;
Sakurai, 2007). In this study, we found that orexin excites
LVN neurons by activation of both OX1 or OX2 receptors and
a dual ionic mechanism including both activation of Na+-Ca2+
exchangers and closure of inward rectifier K+ channels.
The actions of orexin on the activity and sensitivity of LVN
neurons we observed reflect this dual ionic mechanism.
Because the reversal potential of Na+-Ca2+ exchangers is highly
positive (Wu et al., 2004), they are affected little by the fluctuation
of membrane potential and their activation can provide an effi-
cient force for depolarizing neurons. Thus, through activation
of Na+-Ca2+ exchangers orexin depolarizes LVN neurons,
increasing the discharge of spontaneous firing neurons and
evoking firing in silent neurons. In addition, inward rectifier K+
channels that govern the resting membrane potential are shut
off during depolarization and open to help repolarization (Hille,
2001; Nishida and MacKinnon, 2002). Therefore, by closure of
inward rectifier K+ channels, orexin can not only increase firing
rate but delay repolarization that consequently increases sensi-
tivity of LVN neurons. On the other hand, orexin did not change
the accommodation of instantaneous firing rate responded to
the long plateau stimulus, suggesting that orexin does not influ-
ence the dynamic properties or basic response patterns of LVN
neurons, as well as their basic function.
Notably, the activation of orexin on LVN neurons in vivo
influences vestibular-mediated motor behaviors. Unilateral
microinjection of orexin into the LVN elicits postural change,
and bilateral microinjection of orexin promotes motor balance.
These changes result from an enhanced output of LVN induced
by orexin, since we observed an extending of ipsilateral forelimb
and hindlimb following unilateral microinjection, which suggests
an increase in muscle tone. The facilitation of muscle tone
induced by the excitatory action of orexin on the LVN suggests
that decreased orexinergic afferents on LVN may contribute toloss of muscle tone in cataplexy. Moreover, bilateral microinjec-
tion of orexin improves negative geotaxis, which is considered
a general diagnostic of vestibular function and motor skills
(Altman and Sudarshan, 1975; Hermans et al., 1992). Since
negative geotaxis is an automatic, stimulus-bound orientation
movement and considering the linear property in input-output
transduction of central vestibular nuclei (Bagnall et al., 2008),
we speculate that the orexin-induced increase of sensitivity of
LVN neurons may enhance the responsiveness of the central
vestibular circuitry to changes of direction and gravity, leading
to an improvement in negative geotaxis. These behavioral results
strongly suggest that the orexinergic afferents in the LVN may
directly and activelymodulate central vestibular-mediatedmotor
behaviors.
Role of Orexin on Motor Control: Critical for Movements
during Large Motor Challenges
Although previously there was no known involvement of orexin in
the motor system except the cataplexy in orexin knockout
animals (Kukkonen et al., 2002; Matsuki and Sakurai, 2008;
Sakurai, 2007), this study, together with several other recent
reports, indicates a role of the central orexinergic system in
motor control. In this and previous studies, we demonstrate an
excitatory action of orexin on neurons in both the LVN and cere-
bellar nuclei (Yu et al., 2010). Orexin also excites GABAergic
neurons in the substantia nigra reticulata (Korotkova et al.,
2002) and increases the activity and sensitivity of spinal moto-
neurons (Yamuy et al., 2004), although their underlying mecha-
nisms maybe different. The homogeneous excitatory effect of
orexin on these neurons involved in motor control suggests
that the central orexinergic system acts to uniformly and paral-
lelly excite motor structures. Therefore, we speculate that this
common excitation may help these motor structures maintain
excitability at a certain level and also provide for an appropriate
level of sensitivity for responding to inputs coding changes in
internal and external environments. Via biasing neuronal activity
and sensitivity in motor structures, the central orexinergic fibers
may sequentially modulate motor behaviors.
However, an intriguing question is how endogenous orexin
participates in central motor control. Although several studies
reported that orexin neurons are especially active (Estabrooke
et al., 2001; Lee et al., 2005; Mileykovskiy et al., 2005; Torterolo
et al., 2003) and that orexin release increases during movements
(Kiyashchenko et al., 2002; Martins et al., 2004; Wu et al., 2002),
interestingly, orexin knockout animals do not show apparent
motor deficits except during cataplexy (Espan˜a et al., 2007). In
the present study, we suggest a specific position of the central
orexinergic system in motor control. Our results demonstrate
that endogenous orexin is critical for motor control for animals
facing a major motor challenge. Therefore, the modulation of
the central orexinergic system on motor control may be not
readily noticeable when internal and external environments are
relatively stable, as during rest or routine movements. During
a significant behavioral challenge, the increased excitatory drive
and sensitivity due to the release of orexin may be essential for
ensuring prompt and appropriate magnitude motor responses.
Moreover, the stronger the motor challenge faced by animals,
the greater the degree of involvement of the central orexinergicNeuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc. 801
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pected challenge that requires a strong motor response, orexin
deficiency results in cataplexy. Furthermore, given the recent
finding that orexin promotes wakefulness by enhancing locomo-
tion (Anaclet et al., 2009), we suggest that narcolepsy-cataplexy
caused by orexin deficiency may be, in part, a consequence of
loss of orexinergic modulation on the motor system.
Central Orexinergic System: A Potential Neural
Substrate Responsible for Somatic-Nonsomatic
Integration?
The central orexinergic systemhas been implicated inmany non-
somatic basic functions, including sleep/wake states, energy
homeostasis, neuroendocrine, and autonomic functions, and
reward processes (Kukkonen et al., 2002; Matsuki and Sakurai,
2008; Sakurai, 2007). In this study, we revealed that this system
is directly involved in somatic motor control. Thus, through
parallel modulation of both somatic and nonsomatic activities,
the central orexinergic system may help to orchestrate an inte-
grated and coordinated somatic-nonsomatic response that
leads to the appropriate behavioral response to changes in the
internal and external environment. Obviously, an intact behavior
comprises both somatic and nonsomatic components and
needs a somatic-nonsomatic integration involving various brain
regions and discrete neuronal pathways (Zhu et al., 2006a).
Here, we speculate that the central orexinergic system is an
important component of the neural substrates responsible for
somatic-nonsomatic integration. We further suggest that narco-
lepsy-cataplexy caused by orexin deficiency is a simultaneous
somatic and nonsomatic dysfunction in which somatic (motor)
activities and some nonsomatic (sleep and emotional) responses
are not correctly integrated and coordinated.
EXPERIMENTAL PROCEDURES
Quantitative Real-Time RT-PCR and Immunofluorescence
Methods for quantitative real-time RT-PCR and immunofluorescence can be
found in the Supplemental Information online. All experiments completely con-
formed to the U.S. National Institutes of Health Guide for the Care and Use of
Laboratory Animals (NIH Publication 80-23, revised 1996). All efforts were
made to minimize the number of animals used and their suffering.
Electrophysiological Recordings
Coronal brainstem slices (300 mM in thickness) containing the LVN were
prepared with a vibroslicer (VT 1200 S, Leica, Germany) from rats aged
12–16 days, according to the rat brain atlas (Paxinos and Watson, 2007).
The slices were incubated in artificial cerebrospinal fluid (ACSF, composition
in mM: 124 NaCl, 2.5 KCl, 1.25 NaH2PO4, 1.3 MgSO4, 26 NaHCO3, 2 CaCl2
and 10 D-glucose) equilibrated with 95% O2 and 5% CO2 at 35
C ± 0.5C
for at least 1 hour and then maintained at room temperature. During recording
sessions, the slices were transferred to a submerged chamber and continu-
ously superfused with 95% O2 and 5% CO2 oxygenated ACSF at a rate of
2 ml/min maintained at room temperature.
Whole-cell recordings were performed on LVN neurons with borosilicate
glass pipettes (3–5 MU) filled with an internal solution (composition in mM:
140 K-methylsulfate, 7 KCl, 2 MgCl2, 10 HEPES, 0.1 EGTA, 4 Na2-ATP,
0.4 GTP-Tris, adjusted to pH 7.25 with 1 M KOH). During recording sessions,
LVN neurons were verified with an Olympus BX51WI microscope (Japan).
Patch-clamp recordings were acquired with an Axopatch-200B amplifier
(Axon Instruments, USA) and the signals were fed into a computer through
a Digidata-1322A interface (Axon Instruments, USA) for data capture and802 Neuron 69, 793–804, February 24, 2011 ª2011 Elsevier Inc.analysis (pClamp 8.2, Axon Instruments, USA). Neurons were held at a
membrane potential of –60 mV and characterized by injection of rectangular
voltage pulse (5 mV, 50 ms) to monitor the whole-cell membrane capacitance,
series resistance and membrane resistance. Neurons were excluded from the
study if the series resistance was not stable or exceeded 20 MU.
We bathed the slices with orexin-A (10–300 nM, Tocris, UK) and orexin-B
(100 nM, Tocris, UK) to stimulate the recorded neurons. [Ala11, D-Leu15]-
orexin-B (100-300 nM, Tocris, UK) and SB334867 (10 mM, Tocris, UK) were
applied to assess the underlying receptor mechanism. TTX (0.3 mM, Alomone
Labs, Israel), picrotoxin (100 mM, Tocris, UK) and kynurenate (1 mM, Tocris,
UK) were used to confirm the postsynaptic effects of orexin. To assess the
feature of orexin-induced whole cell current and the underlying ionic mecha-
nism, in voltage-clamp recording, current-voltage plots (I-V curves) were
obtained before and during drug application using a slow ramp command
(dV/dt = –10 mV/s, ranged from –65 mV to –120 mV) to allow for attainment
of steady-state conditions. KB-R7943 (50 mM, Alomone Labs, Israel) or SN-6
(10 mM, Tocris, UK), and BaCl2 (1 mM) or tertiapin-Q (100 nM, Tocris, UK)
were applied to block the Na+-Ca2+ exchangers and K+ channels, respectively.
To evaluate the effect of orexin on sensitivity and dynamic properties of LVN
neurons, in current clamp recording, we injected a depolarizing ramp-like
current (Figure 5E1) in the absence or presence of orexin. This consisted of
a 600 ms ramp (–150 pA to 150 pA, slop of 0.5 nA/s) followed by a long plateau
of current (150 pA, 4400 ms) as in previous reports (Ris et al., 2001; Uno et al.,
2003).
For in vivo recordings, all experimental procedures, including anesthesia,
surgery, maintenance of the animals’ physiological status, extracellular
neuronal recording, data acquisition, and histology, have been described
previously (Song et al., 2006; Zhu et al., 2006b). Briefly, we initially anesthe-
tized the rats (230–250 g) with urethane (800 mg/kg) plus a-chloralose
(65 mg/kg) and supplemented when necessary. Unitary discharges of the
neurons were conventionally recorded with a glass electrode filled with 1%
solution of pontamine sky blue in 0.5 M sodium acetate (DC resistance 5–10
MU) and digitally recorded through an A/D interface (Power 1401, CED, UK).
The dot raster displays and PSTHs of neuronal discharges were generated
by the software Spike 2 (CED, UK).
Behavioral Tests
Male rats weighing 230–250 g were used in the behavioral tests. The animals
were individually maintained in a thermoregulated (22C–24C) environment,
and housed under a 12 hr light/dark cycle with lights on at 07:00 a.m. Standard
rat chow and water were available ad libitum.
The rats were anesthetized with sodium pentobarbital 40 mg/kg and
mounted on a stereotaxic frame (1404, David Kopf Instruments, USA) under
aseptic conditions. The lower ends of guide tubes (length 8 mm, o.d.
0.8 mm, i.d. 0.5 mm) were positioned 2.0 mm above the LVN (A10.5  10.8,
L 2.2, and H 6.5, according to the rat brain atlas; Paxinos and Watson,
2007). After the implantation, rats were caged individually and allowed to
recover for at least 72 hr. During the behavioral testing sessions, two stain-
less-steel injection cannulae (length 10 mm, o.d. 0.5 mm, i.d. 0.3 mm) were
inserted to protrude 2 mm beyond the tip of the guide tube and just above
the LVN (to minimize lesioning the nuclei) for microinjection of orexin,
SB334867, and vehicle (1 ml each side, lasting 2 min) using Hamilton syringes.
The animals were randomly divided into 4 groups: (1) sham operation, (2)
microinjected with vehicle, (3) microinjected with orexin-A (dissolved in 0.9%
NaCl), (4) microinjected with SB334867 (dissolved in 0.9% NaCl and 5%
DMSO). The tail-hanging test was first performed following unilateral micro-
injection, whereas balance beam, negative geotaxis, accelerating rota-rod
and open-field tests were conducted following bilateral microinjection. Each
animal was trained daily for at least 10 trials for 3–5 consecutive days in order
to achieve a stable performance on the accelerating rota-rod and balance
beam. All tests started at the same time (10:00 a.m.) each day and each test
was divided into four stages (before, 0 hr, 4 hr, and 24 hr after microinjections).
Tail-Hanging Test
The tail-hanging test was used to assess animals’ posture. The rat was
suspended by its tail with its forepaws on the ground. The total number of
rotations in the direction contralateral to the microinjection site was recorded
for 5 min.
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We assessed motor coordination and balance by measuring the ability of the
animals to traverse a balance beam of 190 cm in length and a diameter of
2.5 cm. A plastic platform (7 cm 3 4 cm) was placed at one end of the rod
as the start, and a black plastic box (15 cm 3 15 cm 3 8 cm) was at the other
end of the rod to motivate the animal to cross the beam. The beamwas placed
horizontally or inclined with an elevation of 40, above a cushion that served to
protect animals that fell. The time taken to traverse the beamwas recorded. To
reduce stress and fatigue, the animals were allowed a 90 s rest between trials.
Negative Geotaxis Test
This test is considered as a diagnostic of vestibular function, reflex develop-
ment, and motor skills (Altman and Sudarshan, 1975; Hermans et al., 1992).
Rats were placed on a 40 incline with their head pointing down the slope,
and the time spent for a turn of 180 upward was recorded. The animals
were allowed a 90 s rest between trials to reduce stress and fatigue.
Accelerating Rota-Rod Test
To assess motor performance during a major motor challenge we used
a commercially available accelerating rota-rod (Ugo Basile, Italy). Animals
were first habituated to low rotation (4 rpm) for 30 s, and then subjected to
two trials of 4–40 rpm acceleration during 300, 180, or 60 s (acceleration
was 0.12, 0.2, and 0.6 rpm/s, respectively), with a 3 min resting interval to
reduce stress and fatigue. The time taken for the rat to fall from the rotating
rod was recorded.
Open-Field Test
A square open field (50 cm 3 50 cm 3 40 cm) lit with a 60 W bulb above the
field was used to assess general motor activity. The floor of the arena was
divided into 25 identical squares of 10 cm length. After placing a rat at the
center of the arena, locomotor activity expressed by the number of crossed
squares and exploratory activity expressed by the number of rearings on
hind feet were recorded during 5 min.
Histological Identification
On the last day of the behavioral tests, the animals were deeply anaesthetized
with an overdose of sodium pentobarbital, and then two insulated stainless
steel wires (o.d. 0.4 mm) with 0.2 mm exposed tip were inserted (10 mm)
into the LVN under the guidance of guide tubes for depositing iron at the site
of injection by passing DC current (10 mA, 20 s). The brain was then removed
and fixed with 10% formaldehyde containing 1% potassium ferrocyanide.
Aweek later, frozen serial coronal sections (80 mm in thickness) were prepared,
and the blue dots indicating injection sites were identified according to the rat
brain atlas (Paxinos and Watson, 2007).
Statistical Analysis
All data are presented as mean ± SEM. The Student’s t test, one-way and
repeated-measures two-way analysis of variance (ANOVA), and Newman-
Keuls post hoc testing was employed for statistical analysis.SUPPLEMENTAL INFORMATION
Supplemental Information includes three figures and Supplemental Experi-
mental Procedures and can be found with this article online at doi:10.1016/j.
neuron.2011.01.026.
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